Sunday, January 04, 2009
Tragic results of suboptimal gynecologic cancer op...[Eur J Gynaecol Oncol. 2008] - PubMed Result
"CONCLUSION: If a gynecologist does not have enough experience or expertise about gynecological cancer operations, he or she must consider the possible harm that any surgical intervention might do, as the latin phrase 'primum non nocere' means and should refer patients to a gynecological oncology center without performing any surgery."
Prospective study of physical activity and the ris...[Cancer Causes Control. 2008] - PubMed Result
"CONCLUSIONS: Neither moderate nor vigorous physical activity showed a statistically significant association with ovarian cancer in this large cohort of women."
Consideration of hereditary nonpolyposis colorectal cancer (HNPCC/Lynch Syndrome) in BRCA mutation negative familial ovarian cancers
Consideration of hereditary nonpolyposis colorecta...[Cancer. 2008] - PubMed Result
"CONCLUSIONS:: HNPCC should be considered when evaluating patients with suspected hereditary ovarian cancer who have had negative BRCA mutation testing"
Clinical trials in Canada: whose interests are par...[Int J Health Serv. 2008] - PubMed Result
Clinical trials in Canada: whose interests are paramount?
More than 80 percent of clinical drug trials in Canada are funded by the pharmaceutical industry. This article evaluates the overall state of clinical trials in Canada and looks at the interplay between public and private interests. Health Canada has adopted standards developed by the International Conference on Harmonization, a body that is heavily influenced by industry. Commercial interests are increasingly involved in recruiting patients into clinical trials and in running these trials. It is in industry's interests to conduct drug tests on people for which it is easiest to see benefits. These interests are not fundamentally challenged by Health Canada's policy of issuing nonmandatory guidelines on who should and should not be included in clinical trials. The outcome of clinical trials is heavily influenced by commercial sponsorship, with the result that trials may favor corporate interests rather than the interests of the public. How Health Canada deals with that possibility is not known, because of its strict policy of treating clinical trial data as private property. If clinical trials are to serve the purpose for which they are designed, developing reliable and objective information about new drugs, then commercial interests cannot be allowed to take precedence over health interests.
A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma
The American Journal of Surgical Pathology - Abstract: Volume 33(1) January 2009 p 14-21 A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma
Medical students' experiences with addicted patien...[Subst Abus. 2008] - PubMed Result
"Students reacted strongly to the psychosocial impact of addictions on patients, yet they viewed addiction as a personal choice, not an illness. Conclusion: Medical students are not being trained to diagnose addiction or provide advice and counseling. Medical schools need to provide students with positive clinical experiences supervised by physicians experienced in addictions."
YouTube - Transcending: Words on Women and Strength by Kelly Corrigan